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Summary To determine if the chemotherapy resistance of non-small cell lung cancer could be modified by
oral verapamil, 72 patients were entered into a randomised trial of verapamil plus chemotherapy vs the same
chemotherapy alone. Verapamil 480 mg day-' was given for 3 days starting 24 h prior to chemotherapy which
consisted of bolus vindesine 7 mg followed by ifosfamide/mesna 5 g m 2 over 24 h, followed by mesna alone
for a further 8 h. Cycles were repeated every 3 weeks for up to six courses. Sixty-six patients were eligible for
tumour response analysis and responses occurred in 41% of those randomised to chemotherapy plus verapamil
and in 18% of those randomised to chemotherapy alone (P = 0.057). Median survival from start of treatment
was significantly better in the verapamil arm (P = 0.02). Toxicity of the combination of chemotherapy plus
verapamil was principally neurological and was manageable. Thus the addition of oral verapamil to vindesine/
ifosfamide chemotherapy is feasible and in this study was associated with improved outcome. Further
confirmation of these observations is required in non-small cell lung cancer, a tumour characterised by
resistance to conventional chemotherapy.
Effective chemotherapy for advanced non-small cell lung
cancer is prevented by the resistance of these tumours to
cytotoxic drugs. Only a limited number of established cyto-
toxic drugs (vindesine, vinblastine, cisplatin, mitomycin-C,
ifosfamide) have single agent anti-tumour activity producing
response rates above 15% (Kris et al., 1986; Ettinger et al.,
1989). Various combinations of single agents have produced
response rates in up to 85% of patients in a large number of
uncontrolled phase II studies (Ettinger, 1989; Splinter, 1990)
but anti-tumour effects were generally lower in randomised
phase III studies where combination chemotherapy has pro-
duced no benefit or only modest improvements in survival
compared to supportive care and at the expense of toxicity
(Woods et al., 1990; Rapp et al., 1988; Ganz et al., 1989).
The basis for tumour resistance to chemotherapy is com-
plex but a widely described mechanism is the multi-drug
resistant phenotype (MDR), a form of cellular resistance
characterized by reduced intracellular drug accumulation
related to a cell membrane glycoprotein termed the P-
glycoprotein. This results in resistance to a variety of func-
tionally and structurally dissimilar cytotoxics including vinca
alkaloids, anthracyclines and etoposide. P-glycoprotein is
present in some normal tissues such as colonic, epithelium,
renal tubules and liver (Fojo et al., 1987) where its function
is postulated to be detoxification of exogenous carcinogens.
Tumours arising from these organs generally express high
levels of P-glycoprotein and are chemo-resistant. RNA slot
blot analysis to measure expression of the gene coding for
P-glycoprotein (the MDR-1 gene) found ;only low levels of
MDR-1 expression in non-small cell lung tumours apart
from a small subgroup that had neuro-endocrine markers
(Lai et al., 1989).
Others have analysed tumour samples for the presence of
P-glycoprotein immunohistochemically and found P-glyco-
protein expressing cells in 76% (Radosevich et al., 1989) and
47% (Volm et al., 1991) of non-small cell lung cancers. Volm
et al. (1991) further demonstrated that expression of P-
glycoprotein was associated with doxorubicin resistance of
the tumour in vitro even when the immunostaining was weak.
These results suggest that the MDR may be an important
cause of the clinical drug resistance of non-small cell lung
cancer.
The characterization of the MDR has lead to the search
for drugs that can inhibit the function of P-glycoprotein and
thus increase the cytotoxicity of those chemotherapy drugs
that are affected by it. The calcium channel blocker vera-
pamil was the first drug shown to be capable of overcoming
P-glycoprotein mediated resistance to vinca-alkaloids in vitro
(Tsuruo et al., 1981). Clinical studies have used verapamil
given by intravenous infusion to produce the highest attain-
able plasma concentrations until limited by cardiovascular
toxicity (Ozols et al., 1987; Miller et al., 1991). With this
approach circulating verapamil levels up to 6JLM (Ozols et
al., 1987) were obtained but inpatient cardiac monitoring was
necessary and despite some success having been achieved in
inducing responses in patients with chemotherapy resistant
lymphoma (Miller et al., 1991) this approach is impractical
for treating large numbers of patients. When verapamil was
given orally verapamil levels of approximately 1 jM were
obtained (Cantwell et al., 1985). Although a level of 1 tsM is
below that required to modulate the MDR in vitro, following
oral administration the metabolite norverapamil is present in
plasma in approximately equal concentration to verapamil
and this metabolite is also effective in modulating MDR
(Merry et al., 1989). After oral verapamil administration first
pass hepatic metabolism results in lower systemic concentra-
tions of the cardiotoxic L(S)-isomer and relatively higher
systemic concentration of the D(R)-isomer which was as
active in modulating the MDR in vitro (Keilhauer et al.,
1989). The circulating plasma level is only an approximation
to the verapamil concentration at the tissue level and in
mammals verapamil and norverapamil may be present in
higher amounts in lung and other tissues than in the circula-
tion (Hamman et al., 1984). Furthermore, MDR expressing
cell lines have usually been made resistant by incremental
increases in the concentration of cytotoxic drug which is
different to the in vivo situation in untreated malignancies
where the degree of resistance may be lower.
In this study the clinical potential of oral verapamil in
combination with a first-line chemotherapy regimen was
investigated in patients with advanced non-small lung cancer.
The cytotoxic drugs chosen were vindesine and ifosfamide,
both active single agents. Resistance to vinca alkaloids is
known to be mediated via the MDR whereas ifosfamide
cytotoxicity is not thought to be influenced by it. Thus
Correspondence: M.J. Millward, Department of Haematology and
Medical Oncology, Peter MacCallum Cancer Institute, 481, Little
Lonsdale Street, Melbourne 3000, Australia.
Received 13 July 1992; and in revised form 7 December 1992.
17" Macmillan Press Ltd., 1993 Br. J. Cancer (1993), 67, 1031-10351032 M.J. MILLWARD et al.
patients with possible P-glycoprotein expressing tumours who
did not receive verapamil would receive a potentially active
cytotoxic agent. The dose of verapamil used was based on
our previous data on oral verapamil and vindesine (Cantwell
et al., 1985) where the maximally tolerated dose was verap-
amil 480 mgday-' for 3 days with vindesine 7 mg, repeated
every 2 weeks. In that study the major toxicities were
neuropathy, constipation and symptomatic postural hypoten-
sion. For the current study the dose interval was increased to
every 3 weeks to allow for recovery from myelosuppression
from the addition of ifosfamide. To reduce the potential bias
from an uncontrolled phase II study and to allow a better
assessment of toxicity a randomised study was performed but
as the combination of verapamil with this chemotherapy had
not previously been examined the investigators were not
blinded and placebo oral medication not used.
Patients and methods
Patients with non-small cell lung cancer (any histologic sub-
type) were eligible if they had either metastatic disease,
locally recurrent disease following surgery and/or radiother-
apy or bulky locally advanced disease considered inoperable
and unsuited for radiation therapy. No prior chemotherapy
was permitted. Normal renal function, normal bilirubin and
normal pretreatment haematological parameters (white cell
count >4.0 x 109 1-l, platelets > 120 x 109 1-') and inform-
ed consent were required. Patients with serious co-existing
cardiovascular disease were excluded.
Following registration patients were randomised to receive
chemotherapy plus verapamil or chemotherapy alone. Chem-
otherapy consisted of intravenous vindesine 7 mg bolus fol-
lowed by ifosfamide 5.0 g m-2 in 3 litres dextrose/saline
infused over 24 h. Mesna was given intravenously 1.0 gm-2
as a bolus prior to ifosfamide, 3.0 g m2 admixed with the
ifosfamide and 1.0 gm2 in 1 litre dextrose/saline over 8 h
following ifosfamide. Verapamil 480mgday-' in three divi-
ded doses was given for 3 days commencing 24 h prior to
chemotherapy. Nadir blood counts were not performed.
Cycles of treatment were repeated every 21 days and patients
re-assessed after two or three cycles. A maximum of six
cycles were given to patients with responding tumours; non-
responders went off study and were treated at the inves-
tigators discretion, but cross-over from the no-verapamil to
the verapamil arm was not permitted.
Response to treatment and toxicity were graded by stan-
dard WHO criteria (WHO, 1979). Differences in proportion
between groups were tested for by the chi-square test and
Fisher's exact test as appropriate. Survival and response
duration curves were analysed by Peto's log-rank test using a
programme for the BBC microcomputer (B Angus). All P
values were 2-sided.
Results
Seventy-two patients were enrolled on study. Three patients
were ineligible (one primary oesophageal carcinoma, two
previous chemotherapy) and for one other patient there was
no documentation. The final analysis therefore contains 68
patients of whom 34 were randomised to chemotherapy plus
verapamil and 34 to chemotherapy alone. The details of these
patients are shown in Table I. Histological subtype was
recorded at initial diagnosis although this is not generally
considered a prognostic factor in such advanced stage pa-
tients and significant inter-observer variability exists (Rosen-
thal et al., 1990). Patients disease extent was recorded as
either locally advanced (including ipsilateral pleural effusion,
ipsilateral supraclavicular nodes and locally recurrent disease)
or metastatic (including metastases in contralateral lung,
bilateral pleural effusions, any extra-thoracic disease other
than ipsilateral supraclavicular nodes and recurrence at other
than the initial primary site). No significant difference was
found between the two arms in age, male/female ratio or
distribution of histological subtype, disease extent, perfor-
mance status or previous treatment.
Response and survival
All 68 patients are evaluable for survival and toxicity and 66
patients are evaluable for response. Three patients ran-
domised to receive verapamil did not receive it because of
concurrent use of nifedipine (two patients) and a beta-
blocker (one patient). These patients are analysed on an
intention-to-treat basis for response and survival, but on an
actual received treatment basis for toxicity. In analysing res-
ponse patients with early death or tumour progression before
planned re-assessment were considered to have progressive
disease. The response rate (Table II) was 41% in the
chemotherapy plus verapamil arm (95% confidence interval
Table II Response to treatment
Verapamil (n = 32) No verapamil (n = 34)
Complete response 2 0
Partial response 11 6
Stable disease 8 5
Progression 11 23
Overall response rate 41% 18%
95% CI 24%-59% 7%-35%
Table I Patient details
Verapamil (n = 34) No verapamil (n = 34)
Age - median
Age - range
Male/Female
Histology
Squamous
Adenocarcinoma
Large cell
Bronchoalveolar
Disease extent
Locally advanced
Metastatic
Performance status
Zero
One
Two
Three
Previous treatment
None
Surgery
Radiotherapy
57 yr
40-74
28/6
17
8
8
1
57 yr
39-77
23/11
9
16
8
1
20
14
20
10
3
P=0.26
P= 0.16
P=0.63
P=0.28
P=0.5
17
17
4
13
13
2
31
2
1
32
1
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24%-59%) and 18% in the chemotherapy alone arm (95%
confidence interval 7%-35%) (P = 0.057).
Two patients who received chemotherapy plus verapamil
and had responses lasting >6 months were retreated with
the same regimen on progression and had second responses.
Eight non-responding patients received further chemotherapy
principally cisplatin or cisplatin plus etoposide with no objec-
tive tumour responses.
At the time of analysis 82% of patients had died of
progressive tumour, 1.5% have died of infection, possibly
treatment related, 1.5% have died of other causes, 10% are
alive with progressive tumour, and 4.5% are alive in res-
ponse. The median duration of response in responding
patients is 36 weeks in both arms (P>0.1). The median
overall survival is 41 weeks in the chemotherapy plus ver-
apamil arm and 22 weeks in the chemotherapy alone arm
(P = 0.02) (Figure 1).
Toxicity
(1) Neurologic (Table III) WHO grade III constipation
(significant abdominal discomfort with distension requiring
treatment) occurred in five patients who received chemo-
therapy plus verapamil. One of these patients required hos-
pital admission for symptomatic treatment but all patients
were able to continue chemotherapy plus verapamil with
concurrent aperients. Another patient developed WHO grade
IV ileus which resolved with intravenous therapy and naso-
gastric suction. This patients had obtained a partial tumour
response and was given further single agent ifosfamide but
verapamil and videsine were discontinued. No constipation
was recorded in the chemotherapy alone arm.
Peripheral neuropathy occurred during treatment in five
patients who received verapamil and one patient who re-
ceived chemotherapy alone. This toxicity was not severe
(WHO grade I/II) and in two patients lead to modification of
the dose of vindesine. Additionally one patient who received
verapamil plus chemotherapy developed impotence following
six cycles of treatment. This was considered to be related to
neurological toxicity and has been reported with vincristine
(Kaplan et al., 1982).
Overall the incidence of peripheral neuropathy or WHO
grade III/IV constipation was 35% in the verapamil arm of
the study. Constipation was manifest by the second cycle in
all patients and peripheral neuropathy by the third cycle in
all patients except the case of impotence.
There was no difference between the arms in the incidence
of ifosfamide related encephalopathy (12% vs 3% P = 0.16).
(2) Cardiovascular Symptomatic postural hypotension dur-
ing the period of verapamil administration occurred in two
100 -a
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0-
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._ 0
0- 0
50
Table HI Neurologic toxicity (% of patients)
Verapamil No verapamil
Constipation 19% 0% P= 0.007
(WHO III/IV)
Peripheral neuropathy 19% 3% P = 0.04
Either 35% 3% P= 0.005
patients. In one patient this was accompanied by bradycardia
(pulse rate 50min-') that resolved with discontinuation of
verapamil. The other patient was able to continue treatment.
No other adverse cardiac events occurred with verapamil. On
the chemotherapy alone arm one patient had a non-fatal
myocardial infarction 2 weeks after the first cycle of chemo-
therapy in the setting of tumour progression. A further
patient on this arm died suddenly of probable cardiac causes
5 months after his last cycle of chemotherapy. This patient
had stable disease following chemotherapy and tumour pro-
gression had not been recorded prior to death.
(3) Other No treatment delays or dose modifications for
myelosuppression were necessary in either arm. One patient
who received verapamil plus chemotherapy died with Haem-
ophilus Influenzae chest infection following the first cycle of
treatment but did not have myelosuppression. One patient in
the chemotherapy alone arm developed a septicaemia with a
white cell count of 0.5 x 1091- that resolved with antibiotic
therapy.
Miscellaneous recorded possible treatment related toxicities
were diarrhoea (two patients), haematuria (one patient;
known to have renal metastases), possible allergic reaction to
ifosfamide (one patient), calf vein thrombosis (one patient)
and development of a broncho-pleural fistula (one patient).
Discussion
This study has shown that the co-administration of oral
verapamil in maximum tolerated dose with a vindesine/
ifosfamide chemotherapy regimen for advanced non-small
cell lung cancer is feasible. The response rate and survival of
patients randomised to receive the combination was superior
to that of patients receiving the same chemotherapy regimen
without verapamil. This suggests that the addition of vera-
pamil increased the anti-tumour activity of chemotherapy.
This observation requires confirmation in a larger trial with
appropriate placebo control.
The most noticeable toxicity observed from the combina-
tion ofverapamil with vindesine/ifosfamide was neurological.
Although constipation is a recognised side effect ofverapamil
A Chemotherapy plus verapamil
0 Chemotherapy without verapamil
0 24 48 72 96 120 144 168 192 216
Time from start oftreatment (wk)
Figure 1 Survival by treatment category.
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it is rarely serious. In a large double-blind trial for the
treatment of hypertension the withdrawal rate from verapa-
mil because of constipation/abdominal cramps was 2% (Hol-
zgreve et al., 1989). Comparison ofgrades ofconstipation are
subjective as WHO grading of toxicity is not used in car-
diovascular trials but the severity of constipation in our
study would certainly have lead to withdrawal of the patients
from long-term verapamil use. Vindesine is less neurotoxic
than vincristine, but has the same spectrum of neurological
toxicity including peripheral neuropathy and constipation
(Kaplan et al., 1982).
Cardiovascular toxicity in this study was minimal and less
than that seen in the initial phase I study (Cantwell et al.,
1985). The low incidence of symptomatic postural hypoten-
sion may have been due to the administration of intravenous
fluids with the ifosfamide and mesna with consequent expan-
sion ofintravascular volume. Other toxicities were also infre-
quent. A precise evaluation of the effect of verapamil on
haematologic toxicity would require nadir blood counts, but
with this limitation we did not find a marked increase in
treatment delays or infectious complications in the verapamil
arm. Vindesine plus ifosfamide in the doses used was not
expected to be a very myelosuppressive combination. Greater
than expected haematologic toxicity has been reported in
patients receiving verapamil with more myelosuppressive
drugs such as doxorubicin (Lai et al., 1990) although this has
not generally been the case (Ozols et al., 1987; Miller et al.,
1991; Dalmark et al., 1991; Wheeler et al., 1988; Milroy et
al., 1991).
There have been few studies attempting to use oral
verapamil as a resistance modifier. In hepatocellular car-
cinoma verapamil with doxorubicin was not superior to
previous experience with doxorubicin alone (Lai et al., 1990)
but the verapamil dose was low (120 mgday-') because of
the presence of hepatic cirrhosis. In contrast in haematologic
malignancies oral verapamil in doses of 240-400mgday-'
with vincristine/doxorubicin containing regimens could in-
duce responses in patients resistant to the same chemo-
therapy alone (Reizenstein, 1990). Two randomised trials in
untreated small cell lung cancer (Wheeler et al., 1988; Milroy
et al., 1991) have not shown significant benefit from adding
oral verapamil to chemotherapy, although the larger study
reported an overall increase in complete response rate and a
longer median survival in patients with extensive disease who
received verapamil (Wheeler et al., 1988). Small cell lung
cancer is significantly less likely to express P-glycoprotein in
untreated cases than non-small cell lung cancer (Radosevich
et al., 1989) as is reflected in the high response rate of
untreated small cell lung cancer to chemotherapy. The stra-
tegy of potentially circumventing MDR in small cell lung
cancer by giving ifosfamide to patients who did not achieve a
complete response after three cycles of MDR selecting drugs
(etoposide, vincristine and doxorubicin) met with only limi-
ted success (Cantwell et al., 1988). The potential value of
resistance modifiers in small cell lung cancer may therefore
be more apparent in patients who relapse after an initial
good response.
The addition of verapamil to chemotherapy results in
several potential interactions and it is not possible with cer-
tainty to determine if the benefit in this trial was directly due
to modulation of MDR. Verapamil may have a significant
pharmacokinetic interaction with doxorubicin (Kerr et al.,
1986). Nifedipine when combined with vincristine resulted in
reduced vincristine clearance and therefore greater systemic
exposure than vincristine given alone (Fedelli et al., 1989),
thus increasing the potential anti-tumour activity and toxicity
although the latter was not clinically apparent (Fedelli et al.,
1989). It is possible that the effects we observed from com-
bining verapamil with vindesine/ifosfamide chemotherapy
were due to a pharmacological interaction. The cardiovas-
cular effects of verapamil may also affect tumour exposure to
cytotoxics by altering tumour blood flow.
This study has shown the possibility of evaluating oral
verapamil in untreated non small cell lung cancer. The results
suggest further exploration of its use and the evaluation of
other potential modifiers of multidrug resistance in this
malignancy. Where possible such studies should attempt to
correlate outcome with sequential measurements of tumour
expression of P-glycoprotein.
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